RxDoctor Payments DataLook up a doctor →

Scott Layne, MD

Internal Medicine · Flowood, MSNPI 1922106749

Payments from drug & device makers

$7,224in general payments, 2019–2025

Across 493 payments — averaging $14.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Pfizer$922
  • Merck$423
  • GSK$406
  • Novartis$306
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,224100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,224 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$318,816
Medicare patients
771
Services billed
3,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban318$270,045
JardianceEmpagliflozin91$102,402
OzempicSemaglutide67$83,064
MounjaroTirzepatide71$69,990
XareltoRivaroxaban51$59,170
JanuviaSitagliptin Phosphate57$55,156
MyrbetriqMirabegron63$47,567
LinzessLinaclotide49$44,995
TrulicityDulaglutide25$42,145
EntrestoSacubitril/Valsartan37$39,567
Tresiba Flextouch U-200Insulin Degludec35$38,719
FarxigaDapagliflozin Propanediol27$31,210
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$22,136
Tresiba Flextouch U-100Insulin Degludec39$21,514
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$17,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Celebrex$922$275,812329 claims
Lilly USA, LLCMounjaro, Trulicity$181$112,13596 claims
Boehringer IngelheimJardiance$293$102,40291 claims
Novo NordiskOzempic$1,023$83,06467 claims
AbbVieLinzess, Synthroid, Restasis, Namzaric$1,530$76,240225 claims
Johnson & JohnsonXarelto$261$59,17051 claims
MerckJanuvia$423$55,15657 claims
Astellas Pharma US IncMyrbetriq$120$47,56763 claims
NovartisEntresto$306$39,56737 claims
AstraZenecaFarxiga$74$31,21027 claims
GSKBreo Ellipta, Trelegy Ellipta$406$26,32750 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$30$5,52712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Flowood

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →